Valentin Zunic is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patent and innovation strategies practice. Val assists clients in the pharmaceutical, chemical, and biotechnology industries on a wide range of intellectual property issues, including strategic patent portfolio development and management, patentability, non-infringement, and freedom to operate.
Val has over a decade of experience representing clients in the life sciences industry, particularly clients pursuing small molecule therapeutics. He has developed and managed patent portfolios for the following representative companies: Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Aragon Pharmaceuticals (acquired by Janssen for its key asset apalutamide (Erleada™)), Pharmacyclics (partnered with Janssen for its key asset ibrutinib (Imbruvica®)), and Seragon Pharmaceuticals (acquired by Roche/Genentech).
Prior to joining the firm, Val was a technology specialist in the San Diego office of Fish & Richardson P.C.
His broad technological background in chemistry includes research experiences as: a medicinal chemist with Vertex Pharmaceuticals and the Genomics Institute of the Novartis Research Foundation; a synthetic organic chemistry graduate student at the University of Toronto examining the synthesis of small organic molecules through the use of (asymmetric) transition metal catalysis; and an undergraduate student studying physical organic chemistry and biomolecular chemistry.
- J.D., University of San Diego School of Law
- Ph.D., Synthetic Organic Chemistry, University of Toronto
- M.S., Synthetic Organic Chemistry, University of Toronto
- B.S., Chemistry, University of Toronto
- State Bar of California
- U.S. Patent and Trademark Office
Rate : $$$